Patents Examined by Gregory S. Emch
  • Patent number: 10981971
    Abstract: A fusion protein used for preventing and treating Alzheimer's disease, a preparation method therefor, and an application thereof. The fusion protein comprises the extracellular domain of human p75NTR human IL-33 and a linker peptide respectively connected to the carboxyl terminus of the p75NTR-ECD and the amino terminus of the human IL-33. The amino acid sequence of the p75NTR-ECD is as shown in SEQ ID NO: 1, and the nucleotide sequence is as shown in SEQ ID NO: 2. The amino acid sequence of the human IL-33 is as shown in SEQ ID NO: 3, and the nucleotide sequence is as shown in SEQ ID NO. 4. The invention overcomes the defects of the p75NTR-ECD or a fusion protein p75NTR-ECD-FC), for preventing and treating Alzheimer's disease. In addition, the functions of the IL-33 and the p75NTR-ECD are combined together, and the biological activity for preventing and treating Alzheimer's disease is significantly increased.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 20, 2021
    Assignee: SHENZHEN PREPHARM BIOMEDICAL TECH CO., LTD.
    Inventor: Junbo Mai
  • Patent number: 10960084
    Abstract: In some embodiments, methods of stimulating fluid intake in a subject in need thereof are described. The methods can comprise stimulating a nitric oxide synthase (nNOS)-positive neuron of the median preoptic nucleus (MnPO). In some embodiments, methods of inhibiting fluid intake in a subject in need thereof are described. The methods can comprise inhibiting stimulation of an nNOS-positive neuron of the MnPO.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 30, 2021
    Assignee: California Institute of Technology
    Inventors: Yuki Oka, Vineet Augustine
  • Patent number: 10921312
    Abstract: The present invention pertains to a method for standardizing the sensitivity of induced pluripotent stem cell (iPS)-derived neurons to a neurotoxin polypeptide, comprising the steps of: a) cultivating different batches of induced pluripotent stem cell-derived neurons in a cell culture medium comprising GT1b for at least 3 hours; b) contacting the different batches of induced pluripotent stem cell-derived neurons of step a) with a neurotoxin polypeptide; c) cultivating the different batches of induced pluripotent stem cell-derived neurons of step b) for at least 24 hours in the presence of GT1b under conditions which allow for the neurotoxin polypeptide to exert its biological activity, thereby standardizing the sensitivity of the induced pluripotent stem cell-derived neurons to a neurotoxin polypeptide.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: February 16, 2021
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventor: Karl-Heinz Eisele
  • Patent number: 10913784
    Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: February 9, 2021
    Assignee: BIOAGE LABS, INC.
    Inventors: Robert Hughes, William Strohl
  • Patent number: 10889618
    Abstract: The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: January 12, 2021
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Dieter Willbold, Susanne Aileen Funke, Oleksander Brener, Luitgard Nagel-Steger, Dirk Bartnik, Antonia Nicole Klein
  • Patent number: 10865229
    Abstract: Provided herein are compositions and methods related to treating repeat expansion diseases that feature the sequestration of Muscleblind-like (MBNL) proteins by the toxic repeat RNA transcripts within distinct nuclear foci that are expressed from the expanded repeat tracts. Certain compositions of synthetic MBLN proteins can be used to displace endogenous MBNL from the toxic RNAs or replace endogenous MBNL within the cell for normal function.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 15, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: John A. Berglund, Melissa Hale
  • Patent number: 10859582
    Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phosphoserine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 8, 2020
    Assignee: New York University
    Inventor: Einar M. Sigurdsson
  • Patent number: 10852309
    Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: December 1, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Lynn R. Zieske, Sarah Hamren
  • Patent number: 10830775
    Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 10, 2020
    Assignee: Washington University
    Inventors: Randall Bateman, Chihiro Sato, Kwasi Mawuenyega, Tim Miller, David Holtzman
  • Patent number: 10809272
    Abstract: The present invention is directed to a biomarker and kit for diagnosing, monitoring and/or staging Alzheimer's disease comprising redox-reactive autoantibodies. The present invention is also directed to a method for diagnosing, monitoring and/or staging Alzheimer's disease which comprises conducting a blood test using the same.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: October 20, 2020
    Assignee: REDOX-REACTIVE REAGENTS, LLC
    Inventor: John A. McIntyre
  • Patent number: 10806795
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 20, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Patent number: 10800820
    Abstract: The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). The hemocyanin is purified using anion exchange chromatography.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: October 13, 2020
    Assignee: Biosyn Arzneimittel GmbH
    Inventors: Ortwin Kottwitz, Thomas Stiefel, Shammana N. Muddukrishna
  • Patent number: 10746747
    Abstract: A method for the quantitative characterization of substances with regard to their properties of binding to amyloid-? (A?) conformers, comprising the steps of: —fractionating a sample including various A? conformers; —immobilizing a biotinylated A? conformer of the desired fraction on the surface of a substrate having high affinity for biotin; and —deriving the binding behavior of an aggregate quality control probe to the desired A? conformer from the measurement signal by determining the kinetic and/or thermodynamic parameters. A device for carrying out the method.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: August 18, 2020
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Dieter Willbold, Julian Glueck, Daniel Frenzel, Luitgard Nagel-Steger, Oleksandr Brener
  • Patent number: 10738115
    Abstract: The present invention relates to antibodies and fragments thereof derived by humanization of an existing antibody, and methods of making them. The humanized antibodies of the present invention show enhanced binding to the brain endothelial antigen, improved transmigration across the blood-brain barrier, and increased thermal stability relative to the parent non-humanized antibody.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: August 11, 2020
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Yves Durocher, Traian Sulea
  • Patent number: 10729728
    Abstract: The present invention refers to a process for preparing an animal brain extract. It also refers to the brain extract obtainable according to said process and to the use thereof as a medicine, in particular for the prevention and/or treatment of neurodegenerative diseases and disorders of the central nervous system. It also refers to compositions comprising this extract and to its use for preparing these compositions.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 4, 2020
    Assignee: BIOIBERICA, S.A.
    Inventors: Josep Escaich Ferrer, Daniel Martinez Puig, Pere Dalmau Castañares, Ramon Ruhi Roura, Joaquima Guix Salichs, Josep Ribas Maynou, Artur Alfocea Egüén, Antonio Garcia Pedrosa, Purificación Morales García, Pere Leon Martín, Marta Badias Eroles
  • Patent number: 10722551
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 28, 2020
    Assignee: Proclara Biosciences, Inc.
    Inventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G. E. Holgate, Timothy D. Jones
  • Patent number: 10724037
    Abstract: The present invention relates to a composition for improving memory including a Cyclin Y (CCNY) inhibitor as an active ingredient. More specifically, the present invention relates to a method for improving memory in a subject comprising administering the composition for improving memory to the subject. The present invention may reveal a CCNY-oriented molecular mechanism with respect to learning and memory, help understand causes of brain diseases associated with memory problems, and ultimately be applied in the treatment and diagnosis of brain memory disorders such as dementia.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: July 28, 2020
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Mikyoung Park, Eunsil Cho, Jung-Hwa Hong
  • Patent number: 10725054
    Abstract: Proteins that are differentially expressed or elevated in tissue and biofluids after central nervous system injuries are described. Elevated or reduced levels of the proteins, alone or in various combinations or ratios, can be used to assess severity of central nervous system injury (CNS injury) including traumatic brain injury (TBI), traumatic spinal cord injury (SCI) and chronic traumatic encephalopathy (CTE). Time course measurements post CNS-injury of these proteins can be used to monitor progress or recovery over periods up to several months. Differentiation of acute, subacute and chronic injury can be diagnosed by comparing the protein levels in CNS-injury patients at days 1-3, day 4-10 with levels at day 30-180 in comparison with normal controls.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 28, 2020
    Assignees: University of Florida Research Foundation, Incorporated, The Research Foundation For The State University of New York
    Inventors: Kevin Ka-Wang Wang, Zhihui Yang, Ahmed Moghieb, Richard Rubenstein
  • Patent number: 10702628
    Abstract: A biomaterial for the treatment of spinal cord or of peripheral nerve injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and culturing and expanding the absorbed cells in the presence of growth or neurotrophic factors selected from ?FGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), BDNF (brain derived neurotrophic factor) and GDNF (glial derived neurotrophic factor) or mixtures thereof.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: July 7, 2020
    Assignee: ANIKA THERAPEUTICS S.R.L.
    Inventors: Alessandra Pavesio, Angelo Vescovi, Fabrizio Gelain, Maurizio Verga
  • Patent number: 10703808
    Abstract: Provided are novel human ?-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 7, 2020
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock